Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07201558 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

A Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
19
Study locations

NCT07201558 is a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 48 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 19 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07201558, a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
19
Study locations

Study Summary

This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

Conditions Studied

Rheumatoid Arthritis Systemic Lupus Erythematosus

Interventions

  • BIOLOGICAL Surovatamig

Study Locations (19)

Other

  • Research Site - Birtinya
  • Research Site - Clayton
  • Research Site - Antwerp
  • Research Site - Porto Alegre
  • Research Site - Beijing
  • Research Site - Nanjing
  • Research Site - Bonn
  • Research Site - Mainz
  • Research Site - München
  • Research Site - Barcelona
  • Research Site - Córdoba
  • Research Site - Madrid
  • Research Site - Kaohsiung City
  • Research Site - Kyiv
  • Research Site - Ternopil
  • Research Site - Vinnytsia

Alabama

  • Research Site - Birmingham

California

  • Research Site - Fullerton

Texas

  • Research Site - Allen

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-12-02
Est. Completion 2028-06-27
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07201558

The ClinicalTrials.gov registry entry for NCT07201558 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Surovatamig is the first listed.

NCT07201558 reports 19 study locations spanning 4 distinct geographic areas - top geographies include Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT07201558 about?

NCT07201558 is a clinical study titled "Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants". This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

What is the current status of trial NCT07201558?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-12-02. Estimated completion is 2028-06-27.

What conditions does trial NCT07201558 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT07201558?

The interventions under investigation include: Surovatamig (BIOLOGICAL).

Who is sponsoring clinical trial NCT07201558?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07201558 being conducted?

This trial has 19 study locations across Alabama, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Systemic Lupus Erythematosus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.